Neurosecretory Systems
FDA clears Exelixis’ TKI for neuroendocrine tumours
CABOMETYX, cabozantinib, neuroendocrine tumors, FDA approval, Exelixis, tyrosine kinase inhibitor
ITM Reports Positive Phase 3 Data for Radiopharmaceutical ITM-11 in Neuroendocrine Tumors, Challenging Novartis’ Lutathera
ITM-11, radiopharmaceutical, Phase 3 COMPETE trial, neuroendocrine tumors, Lutathera, Novartis
ITM’s Radiopharmaceutical ITM-11 Shows Promising Results in Phase III COMPOSE Trial for Advanced Neuroendocrine Tumors
ITM-11, neuroendocrine tumors, GEP-NETs, COMPOSE trial, targeted radionuclide therapy, 177Lu-edotreotide
Sanofi Enters Radiopharmaceutical Market with $110M Licensing Deal for AlphaMedix, Challenging Novartis’ Dominance
Sanofi, radiopharmaceuticals, radioligand therapy, AlphaMedix, Novartis, neuroendocrine tumors, cancer treatment, pharmaceutical industry
Sanofi Enters Radiopharmaceutical Market with $110 Million Licensing Agreement
Sanofi, Radiopharmaceuticals, Licensing Deal, RadioMedix, Orano Med, AlphaMedix, Neuroendocrine Tumors
Merck & Co., Daiichi Sankyo Strengthen Partnership with New DLL3 Cancer Drug Agreement
Merck & Co., Daiichi Sankyo, DLL3, T-cell engager, MK-6070, small cell lung cancer, neuroendocrine tumors, antibody-drug conjugates, oncology pipeline
RayzeBio Warned of Potential Actinium Isotope Supply Issues Before $4.1B BMS Deal
RayzeBio, Bristol Myers Squibb, Actinium-225, Isotope Supply Issues, Radiopharmaceuticals, Neuroendocrine Tumors